Sign inJoin waitlistJoin the waitlist

Lara Hathout

Director of Brachytherapy, Department of Radiation Oncology · Rutgers Health

Credentials: · · · ·

History

Memorial Sloan Kettering Cancer Center
2013–2014
Université de Montréal
2009–2013
Preliminary or Transitional Year
2008–2009
School
2004–2008

Research

Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints…
International journal of radiation oncology · 2014 · First of 6 authors · 78 citations
Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice Guideline
Systematic review or meta-analysis · Practical Radiation Oncology · 2023 · 77 citations
Factors Associated with Anxiety About Colonoscopy: The Preparation, the Procedure, and the Anticipated Findings
Digestive Diseases and Sciences · 2018 · 59 citations

Salma Jabbour
18 papers
EF
Emma Fields
12 papers
Matthew Deek
10 papers · 2 as a resident
Neil Taunk
10 papers · 4 as a resident
Kevin Albuquerque
8 papers
Mohamed Elshaikh
8 papers
Ronald Ennis
8 papers
Sushil Beriwal
8 papers
Zohaib Sherwani
8 papers · 8 as a resident
Junzo Chino
7 papers
Elizabeth Kidd
6 papers
Mutlay Sayan
6 papers · 4 as a resident

Clinical trials

Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer
Principal investigator · Recruiting
Rutgers, The State University of New Jersey
2026–2029
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
Principal investigator · Active not recruiting · Phase 2
Rutgers, The State University of New Jersey
2019–2027
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2041